Skip to Content
 
Dana M.  Brantley-Sieders

Dana M. Brantley-Sieders, Ph.D.

Research Assistant Professor of Medicine: Rheumatology and Immunology

Contact Information:

T-3107A Medical Center North
1161 21st Avenue South
Nashville, TN 37232-2681
616-343-4783
Fax: 615-322-6248

Profile

Our research program focuses on molecular mechanisms that regulate breast tumor growth, tumor angiogenesis, and host-tumor interactions. Members of the Eph family of receptor tyrosine kinases regulate cell growth/survival, motility, and angiogenic remodeling during embryogenesis. More recently, several members of this family have been linked to tumor progression and neovascularization, including breast cancer.
Read more...

Our research program focuses on molecular mechanisms that regulate breast tumor growth, tumor angiogenesis, and host-tumor interactions. Members of the Eph family of receptor tyrosine kinases regulate cell growth/survival, motility, and angiogenic remodeling during embryogenesis. More recently, several members of this family have been linked to tumor progression and neovascularization, including breast cancer.

Overexpression of one family member in particular, EphA2, correlates negatively with overall and recurrence-free survival in breast cancer patients. Our laboratory along with others has linked EphA2 signaling to Erk-dependent growth and Rac-dependent invasion in cell culture and animal models of breast cancer, as well as neovascularization and Herceptin-resistance. Moreover, EphA2 physically and functionally interacts with EGF receptor family members, including EGFR and HER2, in the context of breast cancer. More recently, we found EphA2 expression levels are highest within the triple negative/basal-like subtype of breast cancer. Thus, EphA2 represents a new molecular target for cancer therapy, especially given its simultaneous influence on both tumor cells and the blood vessels within the surrounding microenvironment.

Ongoing studies in the laboratory focus on:

1. The role of EphA2 ligand-independent signaling in lipid metabolism in the context of breast cancer

2. The role of EphA2 signaling in triple negative/basal-like breast cancer growth and invasion

3. The role of EphA2 in angiocrine-mediated breast cancer growth and invasion

Education
  • Ph.D. in Cell Biology, Vanderbilt University (2000)
Research Description

Our research program focuses on molecular mechanisms that regulate breast tumor growth, tumor angiogenesis, and host-tumor interactions. Members of the Eph family of receptor tyrosine kinases regulate cell growth/survival, motility, and angiogenic remodeling during embryogenesis. More recently, several members of this family have been linked to tumor progression and neovascularization, including breast cancer.

Overexpression of one family member in particular, EphA2, correlates negatively with overall and recurrence-free survival in breast cancer patients. Our laboratory along with others has linked EphA2 signaling to Erk-dependent growth and Rac-dependent invasion in cell culture and animal models of breast cancer, as well as neovascularization and Herceptin-resistance. Moreover, EphA2 physically and functionally interacts with EGF receptor family members, including EGFR and HER2, in the context of breast cancer. More recently, we found EphA2 expression levels are highest within the Triple negative/basal-like subtype of breast cancer. Thus, EphA2 represents a new molecular target for cancer therapy, especially given its simultaneous influence on both tumor cells and the blood vessels within the surrounding microenvironment.

Ongoing studies in the laboratory focus on:

1. The role of EphA2 ligand-independent signaling in lipid metabolism in the context of breast cancer
2. The role of EphA2 signaling in Triple Negative/basal-like breast cancer growth and invasion
3. The role of EphA2 in angiocrine-mediated breast cancer growth and invasion

Publications
  • Morrison-Joly M, Hicks DJ, Jones B, Sanchez V, Estrada MV, Young C, Williams M, Rexer BN, Sarbassov DD, Muller WJ, Brantley-Sieders D, Cook RS. Rictor/mTORC2 drives progression and therapeutic resistance of HER2-amplified breast cancers. Cancer Res [print-electronic]. 2016 Apr 4/25/2016; PMID: 27197158, PII: 0008-5472.CAN-15-3393, DOI: 10.1158/0008-5472.CAN-15-3393, ISSN: 1538-7445.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/27197158.
  • Youngblood VM, Kim LC, Edwards DN, Hwang Y, Santapuram PR, Stirdivant SM, Lu P, Ye F, Brantley-Sieders DM, Chen J. The Ephrin-A1/EPHA2 Signaling Axis Regulates Glutamine Metabolism in HER2-Positive Breast Cancer. Cancer Res [print-electronic]. 2016 Apr 4/1/2016; 76(7): 1825-36. PMID: 26833123, PMCID: PMC4873477, PII: 0008-5472.CAN-15-0847, DOI: 10.1158/0008-5472.CAN-15-0847, ISSN: 1538-7445.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26833123.
  • Takahashi K, Sumarriva K, Kim R, Jiang R, Brantley-Sieders DM, Chen J, Mernaugh RL, Takahashi T. Determination of the CD148-Interacting Region in Thrombospondin-1. PLoS ONE. 2016; 11(5): e0154916. PMID: 27149518, PMCID: PMC4858292, PII: PONE-D-15-55087, DOI: 10.1371/journal.pone.0154916, ISSN: 1932-6203.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/27149518.
  • Morrison MM, Young CD, Wang S, Sobolik T, Sanchez VM, Hicks DJ, Cook RS, Brantley-Sieders DM. MTOR Directs Breast Morphogenesis through the PKC-alpha-Rac1 Signaling Axis. PLoS Genet. 2015 Jul; 11(7): e1005291. PMID: 26132202, PMCID: PMC4488502, PII: PGENETICS-D-14-03145, DOI: 10.1371/journal.pgen.1005291, ISSN: 1553-7404.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26132202.
  • Young CD, Zimmerman LJ, Hoshino D, Formisano L, Hanker AB, Gatza ML, Morrison MM, Moore PD, Whitwell CA, Dave B, Stricker T, Bhola NE, Silva GO, Patel P, Brantley-Sieders DM, Levin M, Horiates M, Palma NA, Wang K, Stephens PJ, Perou CM, Weaver AM, O'Shaughnessy JA, Chang JC, Park BH, Liebler DC, Cook RS, Arteaga CL. Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer. Mol. Cell Proteomics [print-electronic]. 2015 Jul; 14(7): 1959-76. PMID: 25953087, PMCID: PMC4587316, PII: M115.049783, DOI: 10.1074/mcp.M115.049783, ISSN: 1535-9484.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25953087.
  • Fang WB, Yao M, Jokar I, Alhakamy N, Berkland C, Chen J, Brantley-Sieders D, Cheng N. The CCL2 chemokine is a negative regulator of autophagy and necrosis in luminal B breast cancer cells. Breast Cancer Res. Treat [print-electronic]. 2015 Apr; 150(2): 309-20. PMID: 25744294, PMCID: PMC4456035, DOI: 10.1007/s10549-015-3324-4, ISSN: 1573-7217.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25744294.
  • Wang S, Amato KR, Song W, Youngblood V, Lee K, Boothby M, Brantley-Sieders DM, Chen J. Regulation of endothelial cell proliferation and vascular assembly through distinct mTORC2 signaling pathways. Mol. Cell. Biol [print-electronic]. 2015 Apr; 35(7): 1299-313. PMID: 25582201, PMCID: PMC4355541, PII: MCB.00306-14, DOI: 10.1128/MCB.00306-14, ISSN: 1098-5549.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25582201.
  • Youngblood V, Wang S, Song W, Walter D, Hwang Y, Chen J, Brantley-Sieders DM. Elevated Slit2 Activity Impairs VEGF-Induced Angiogenesis and Tumor Neovascularization in EphA2-Deficient Endothelium. Mol. Cancer Res [print-electronic]. 2015 Mar; 13(3): 524-37. PMID: 25504371, PMCID: PMC4416411, PII: 1541-7786.MCR-14-0142, DOI: 10.1158/1541-7786.MCR-14-0142, ISSN: 1557-3125.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25504371.
  • Stanford JC, Young C, Hicks D, Owens P, Williams A, Vaught DB, Morrison MM, Lim J, Williams M, Brantley-Sieders DM, Balko JM, Tonetti D, Earp HS, Cook RS. Efferocytosis produces a prometastatic landscape during postpartum mammary gland involution. J. Clin. Invest [print-electronic]. 2014 Nov; 124(11): 4737-52. PMID: 25250573, PMCID: PMC4347249, PII: 76375, DOI: 10.1172/JCI76375, ISSN: 1558-8238.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25250573.
  • Song W, Ma Y, Wang J, Brantley-Sieders D, Chen J. JNK signaling mediates EPHA2-dependent tumor cell proliferation, motility, and cancer stem cell-like properties in non-small cell lung cancer. Cancer Res [print-electronic]. 2014 May 5/1/2014; 74(9): 2444-54. PMID: 24607842, PMCID: PMC4008716, PII: 0008-5472.CAN-13-2136, DOI: 10.1158/0008-5472.CAN-13-2136, ISSN: 1538-7445.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24607842.
  • Amato KR, Wang S, Hastings AK, Youngblood VM, Santapuram PR, Chen H, Cates JM, Colvin DC, Ye F, Brantley-Sieders DM, Cook RS, Tan L, Gray NS, Chen J. Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC. J. Clin. Invest [print-electronic]. 2014 May; 124(5): 2037-49. PMID: 24713656, PMCID: PMC4001547, PII: 72522, DOI: 10.1172/JCI72522, ISSN: 1558-8238.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24713656.
  • Amato KR, Wang S, Hastings AK, Youngblood VM, Santapuram PR, Chen H, Cates JM, Colvin DC, Ye F, Brantley-Sieders DM, Cook RS, Tan L, Gray NS, Chen J.. Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC. 2014;
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24713656.
  • Stanford JC, Young C, Hicks D, Owens P, Williams A, Vaught DB, Morrison MM, Lim J, Williams M, Brantley-Sieders DM, Balko JM, Tonetti D, Earp HS 3rd, Cook RS.. Efferocytosis produces a prometastatic landscape during postpartum mammary gland involution. 2014;
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25250573.
  • Zhuang G, Song W, Amato K, Hwang Y, Lee K, Boothby M, Ye F, Guo Y, Shyr Y, Lin L, Carbone DP, Brantley-Sieders DM, Chen J. Effects of cancer-associated EPHA3 mutations on lung cancer. J. Natl. Cancer Inst [print-electronic]. 2012 Aug 8/8/2012; 104(15): 1182-97. PMID: 22829656, PMCID: PMC3611812, PII: djs297, DOI: 10.1093/jnci/djs297, ISSN: 1460-2105.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22829656.
  • Brantley-Sieders DM. Clinical relevance of Ephs and ephrins in cancer: lessons from breast, colorectal, and lung cancer profiling. Semin. Cell Dev. Biol [print-electronic]. 2012 Feb; 23(1): 102-8. PMID: 22040912, PMCID: PMC3288332, PII: S1084-9521(11)00202-3, DOI: 10.1016/j.semcdb.2011.10.014, ISSN: 1096-3634.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22040912.
  • Brantley-Sieders DM, Fan KH, Deming-Halverson SL, Shyr Y, Cook RS. Local breast cancer spatial patterning: a tool for community health resource allocation to address local disparities in breast cancer mortality. PLoS ONE [print-electronic]. 2012; 7(9): e45238. PMID: 23028869, PMCID: PMC3460936, PII: PONE-D-12-12178, DOI: 10.1371/journal.pone.0045238, ISSN: 1932-6203.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23028869.
  • Rao M, Song W, Jiang A, Shyr Y, Lev S, Greenstein D, Brantley-Sieders D, Chen J. VAMP-associated protein B (VAPB) promotes breast tumor growth by modulation of Akt activity. PLoS ONE [print-electronic]. 2012; 7(10): e46281. PMID: 23049696, PMCID: PMC3462209, PII: PONE-D-12-16139, DOI: 10.1371/journal.pone.0046281, ISSN: 1932-6203.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23049696.
  • Brantley-Sieders DM, Dunaway CM, Rao M, Short S, Hwang Y, Gao Y, Li D, Jiang A, Shyr Y, Wu JY, Chen J. Angiocrine factors modulate tumor proliferation and motility through EphA2 repression of Slit2 tumor suppressor function in endothelium. Cancer Res [print-electronic]. 2011 Feb 2/1/2011; 71(3): 976-87. PMID: 21148069, PMCID: PMC3032824, PII: 0008-5472.CAN-10-3396, DOI: 10.1158/0008-5472.CAN-10-3396, ISSN: 1538-7445.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21148069.
  • Dunaway CM, Hwang Y, Lindsley CW, Cook RS, Wu JY, Boothby M, Chen J, Brantley-Sieders DM. Cooperative signaling between Slit2 and Ephrin-A1 regulates a balance between angiogenesis and angiostasis. Mol. Cell. Biol [print-electronic]. 2011 Feb; 31(3): 404-16. PMID: 21135133, PMCID: PMC3028625, PII: MCB.00667-10, DOI: 10.1128/MCB.00667-10, ISSN: 1098-5549.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21135133.
  • Brantley-Sieders DM, Jiang A, Sarma K, Badu-Nkansah A, Walter DL, Shyr Y, Chen J. Eph/ephrin profiling in human breast cancer reveals significant associations between expression level and clinical outcome. PLoS ONE [print-electronic]. 2011; 6(9): e24426. PMID: 21935409, PMCID: PMC3174170, PII: PONE-D-11-14906, DOI: 10.1371/journal.pone.0024426, ISSN: 1932-6203.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21935409.
  • Zhuang G, Brantley-Sieders DM, Vaught D, Yu J, Xie L, Wells S, Jackson D, Muraoka-Cook R, Arteaga C, Chen J. Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res [print-electronic]. 2010 Jan 1/1/2010; 70(1): 299-308. PMID: 20028874, PMCID: PMC3859619, PII: 0008-5472.CAN-09-1845, DOI: 10.1158/0008-5472.CAN-09-1845, ISSN: 1538-7445.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/20028874.
  • Brantley-Sieders DM, Zhuang G, Vaught D, Freeman T, Hwang Y, Hicks D, Chen J. Host deficiency in Vav2/3 guanine nucleotide exchange factors impairs tumor growth, survival, and angiogenesis in vivo. Mol. Cancer Res [print-electronic]. 2009 May; 7(5): 615-23. PMID: 19435813, PMCID: PMC2739740, PII: 1541-7786.MCR-08-0401, DOI: 10.1158/1541-7786.MCR-08-0401, ISSN: 1541-7786.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19435813.
  • Vaught D, Chen J, Brantley-Sieders DM. Regulation of mammary gland branching morphogenesis by EphA2 receptor tyrosine kinase. Mol. Biol. Cell [print-electronic]. 2009 May; 20(10): 2572-81. PMID: 19321667, PMCID: PMC2682598, PII: E08-04-0378, DOI: 10.1091/mbc.E08-04-0378, ISSN: 1939-4586.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19321667.
  • Li B, Vincent A, Cates J, Brantley-Sieders DM, Polk DB, Young PP. Low levels of tumor necrosis factor alpha increase tumor growth by inducing an endothelial phenotype of monocytes recruited to the tumor site. Cancer Res. 2009 Jan 1/1/2009; 69(1): 338-48. PMID: 19118019, PMCID: PMC2651676, PII: 69/1/338, DOI: 10.1158/0008-5472.CAN-08-1565, ISSN: 1538-7445.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19118019.
  • Fang WB, Brantley-Sieders DM, Hwang Y, Ham AJ, Chen J. Identification and functional analysis of phosphorylated tyrosine residues within EphA2 receptor tyrosine kinase. J. Biol. Chem [print-electronic]. 2008 Jun 6/6/2008; 283(23): 16017-26. PMID: 18387945, PMCID: PMC2414276, PII: M709934200, DOI: 10.1074/jbc.M709934200, ISSN: 0021-9258.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/18387945.
  • Brantley-Sieders DM, Zhuang G, Hicks D, Fang WB, Hwang Y, Cates JM, Coffman K, Jackson D, Bruckheimer E, Muraoka-Cook RS, Chen J. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J. Clin. Invest. 2008 Jan; 118(1): 64-78. PMID: 18079969, PMCID: PMC2129239, DOI: 10.1172/JCI33154, ISSN: 0021-9738.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/18079969.
  • Vaught D, Brantley-Sieders DM, Chen J. Eph receptors in breast cancer: roles in tumor promotion and tumor suppression. Breast Cancer Res [print-electronic]. 2008; 10(6): 217. PMID: 19144211, PMCID: PMC2656900, PII: bcr2207, DOI: 10.1186/bcr2207, ISSN: 1465-542X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19144211.
  • Brantley-Sieders DM, Fang WB, Hwang Y, Hicks D, Chen J. Ephrin-A1 facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism mediated by EphA receptor and vascular endothelial growth factor in mice. Cancer Res. 2006 Nov 11/1/2006; 66(21): 10315-24. PMID: 17079451, PII: 66/21/10315, DOI: 10.1158/0008-5472.CAN-06-1560, ISSN: 0008-5472.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/17079451.
  • Tang T, Shi Y, Opalenik SR, Brantley-Sieders DM, Chen J, Davidson JM, Brandt SJ. Expression of the TAL1/SCL transcription factor in physiological and pathological vascular processes. J. Pathol. 2006 Sep; 210(1): 121-9. PMID: 16841371, DOI: 10.1002/path.2028, ISSN: 0022-3417.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/16841371.
  • Hunter SG, Zhuang G, Brantley-Sieders D, Swat W, Cowan CW, Chen J. Essential role of Vav family guanine nucleotide exchange factors in EphA receptor-mediated angiogenesis. Mol. Cell. Biol. 2006 Jul; 26(13): 4830-42. PMID: 16782872, PMCID: PMC1489141, PII: 26/13/4830, DOI: 10.1128/MCB.02215-05, ISSN: 0270-7306.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/16782872.
  • Chen J, Hicks D, Brantley-Sieders D, Cheng N, McCollum GW, Qi-Werdich X, Penn J. Inhibition of retinal neovascularization by soluble EphA2 receptor. Exp. Eye Res [print-electronic]. 2006 Apr; 82(4): 664-73. PMID: 16359662, PII: S0014-4835(05)00293-9, DOI: 10.1016/j.exer.2005.09.004, ISSN: 0014-4835.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/16359662.
  • Fang WB, Brantley-Sieders DM, Parker MA, Reith AD, Chen J. A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis. Oncogene. 2005 Nov 11/24/2005; 24(53): 7859-68. PMID: 16103880, PII: 1208937, DOI: 10.1038/sj.onc.1208937, ISSN: 0950-9232.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/16103880.
  • Brantley-Sieders DM, Fang WB, Hicks DJ, Zhuang G, Shyr Y, Chen J. Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression. FASEB J [print-electronic]. 2005 Nov; 19(13): 1884-6. PMID: 16166198, PII: 05-4038fje, DOI: 10.1096/fj.05-4038fje, ISSN: 1530-6860.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/16166198.
  • Brantley-Sieders DM, Caughron J, Hicks D, Pozzi A, Ruiz JC, Chen J. EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation. J. Cell. Sci [print-electronic]. 2004 Apr 4/15/2004; 117(Pt 10): 2037-49. PMID: 15054110, PII: jcs.01061, DOI: 10.1242/jcs.01061, ISSN: 0021-9533.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/15054110.
  • Schneider C, Strayhorn WD, Brantley DM, Nanney LB, Yull FE, Brash AR. Upregulation of 8-lipoxygenase in the dermatitis of IkappaB-alpha-deficient mice. J. Invest. Dermatol. 2004 Mar; 122(3): 691-8. PMID: 15086555, PII: JID22329, DOI: 10.1111/j.0022-202X.2004.22329.x, ISSN: 0022-202X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/15086555.
  • Brantley-Sieders D, Schmidt S, Parker M, Chen J. Eph receptor tyrosine kinases in tumor and tumor microenvironment. Curr. Pharm. Des. 2004; 10(27): 3431-42. PMID: 15544526, ISSN: 1381-6128.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/15544526.
  • Brantley-Sieders DM, Chen J. Eph receptor tyrosine kinases in angiogenesis: from development to disease. Angiogenesis. 2004; 7(1): 17-28. PMID: 15302992, PII: 5272546, DOI: 10.1023/B:AGEN.0000037340.33788.87, ISSN: 0969-6970.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/15302992.
  • Muraoka RS, Koh Y, Roebuck LR, Sanders ME, Brantley-Sieders D, Gorska AE, Moses HL, Arteaga CL. Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor beta1. Mol. Cell. Biol. 2003 Dec; 23(23): 8691-703. PMID: 14612410, PMCID: PMC262670, ISSN: 0270-7306.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/14612410.
  • Cheng N, Brantley DM, Liu H, Lin Q, Enriquez M, Gale N, Yancopoulos G, Cerretti DP, Daniel TO, Chen J. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol. Cancer Res. 2002 Nov; 1(1): 2-11. PMID: 12496364, ISSN: 1541-7786.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/12496364.
  • Brantley DM, Cheng N, Thompson EJ, Lin Q, Brekken RA, Thorpe PE, Muraoka RS, Cerretti DP, Pozzi A, Jackson D, Lin C, Chen J. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene. 2002 Oct 10/10/2002; 21(46): 7011-26. PMID: 12370823, DOI: 10.1038/sj.onc.1205679, ISSN: 0950-9232.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/12370823.
  • Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, Easterly E, Roebuck LR, Ryan S, Gotwals PJ, Koteliansky V, Arteaga CL. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J. Clin. Invest. 2002 Jun; 109(12): 1551-9. PMID: 12070302, PMCID: PMC151012, DOI: 10.1172/JCI15234, ISSN: 0021-9738.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/12070302.
  • Muraoka RS, Lenferink AE, Law B, Hamilton E, Brantley DM, Roebuck LR, Arteaga CL. ErbB2/Neu-induced, cyclin D1-dependent transformation is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells. Mol. Cell. Biol. 2002 Apr; 22(7): 2204-19. PMID: 11884607, PMCID: PMC133673, ISSN: 0270-7306.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/11884607.
  • Cheng N, Brantley DM, Chen J. The ephrins and Eph receptors in angiogenesis. Cytokine Growth Factor Rev. 2002 Feb; 13(1): 75-85. PMID: 11750881, PII: S1359610101000314, ISSN: 1359-6101.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/11750881.
  • Bushdid PB, Chen CL, Brantley DM, Yull F, Raghow R, Kerr LD, Barnett JV. NF-kappaB mediates FGF signal regulation of msx-1 expression. Dev. Biol. 2001 Sep 9/1/2001; 237(1): 107-15. PMID: 11518509, PII: S0012-1606(01)90356-2, DOI: 10.1006/dbio.2001.0356, ISSN: 0012-1606.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/11518509.
  • Muraoka RS, Lenferink AE, Simpson J, Brantley DM, Roebuck LR, Yakes FM, Arteaga CL. Cyclin-dependent kinase inhibitor p27(Kip1) is required for mouse mammary gland morphogenesis and function. J. Cell Biol. 2001 May 5/28/2001; 153(5): 917-32. PMID: 11381079, PMCID: PMC2174338, ISSN: 0021-9525.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/11381079.
  • Brantley DM, Chen CL, Muraoka RS, Bushdid PB, Bradberry JL, Kittrell F, Medina D, Matrisian LM, Kerr LD, Yull FE. Nuclear factor-kappaB (NF-kappaB) regulates proliferation and branching in mouse mammary epithelium. Mol. Biol. Cell. 2001 May; 12(5): 1445-55. PMID: 11359934, PMCID: PMC34596, ISSN: 1059-1524.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/11359934.
  • Brantley DM, Yull FE, Muraoka RS, Hicks DJ, Cook CM, Kerr LD. Dynamic expression and activity of NF-kappaB during post-natal mammary gland morphogenesis. Mech. Dev. 2000 Oct; 97(1-2): 149-55. PMID: 11025216, PII: S0925477300004056, ISSN: 0925-4773.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/11025216.
  • Muraoka RS, Bushdid PB, Brantley DM, Yull FE, Kerr LD. Mesenchymal expression of nuclear factor-kappaB inhibits epithelial growth and branching in the embryonic chick lung. Dev. Biol. 2000 Sep 9/15/2000; 225(2): 322-38. PMID: 10985853, PII: S0012-1606(00)99824-5, DOI: 10.1006/dbio.2000.9824, ISSN: 0012-1606.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/10985853.
  • Bushdid PB, Brantley DM, Yull FE, Blaeuer GL, Hoffman LH, Niswander L, Kerr LD. Inhibition of NF-kappaB activity results in disruption of the apical ectodermal ridge and aberrant limb morphogenesis. Nature. 1998 Apr 4/9/1998; 392(6676): 615-8. PMID: 9560159, DOI: 10.1038/33435, ISSN: 0028-0836.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/9560159.
  • Dana M Brantley. Apolipoprotein E synthesis by transplanted bone marrow derived cells in apolipoprotein E deficient mice. BIOS. 1996; 67: 74-82.